HC Wainwright Has Positive Outlook for Edap Tms Q1 Earnings

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Edap Tms to ($0.18) from ($0.22), trimmed near‑term loss forecasts, and maintained a Buy rating with a $10 price target.
• Despite that bullish view, the consensus on MarketBeat is a Hold (average target $6), and Edap missed Q1 EPS (($0.25) vs. consensus ($0.16)) while reporting negative margins and continued multi‑year losses, with the stock trading around $3.30.

Edap Tms S.A. (NASDAQ:EDAP - Free Report) - HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Edap Tms in a report released on Thursday, April 9th. HC Wainwright analyst S. Ramakanth now anticipates that the medical equipment provider will post earnings of ($0.18) per share for the quarter, up from their previous forecast of ($0.22). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Edap Tms' current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Edap Tms' Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.54) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at ($0.10) EPS.

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Edap Tms from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edap Tms in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $6.00.

Edap Tms Price Performance

EDAP opened at $3.30 on Monday. The business's 50-day moving average is $4.11 and its two-hundred day moving average is $3.23. Edap Tms has a 1 year low of $1.21 and a 1 year high of $5.05. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.19. The firm has a market capitalization of $123.68 million, a PE ratio of -4.29 and a beta of -0.09.

Edap Tms (NASDAQ:EDAP - Get Free Report) last posted its earnings results on Wednesday, March 25th. The medical equipment provider reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Edap Tms had a negative net margin of 41.24% and a negative return on equity of 100.07%. The company had revenue of $22.22 million during the quarter, compared to analysts' expectations of $21.28 million.

Institutional Investors Weigh In On Edap Tms

Large investors have recently bought and sold shares of the company. Leonteq Securities AG purchased a new stake in Edap Tms in the fourth quarter valued at approximately $313,000. Kovack Advisors Inc. purchased a new stake in Edap Tms in the fourth quarter valued at approximately $53,000. Rock Springs Capital Management LP boosted its position in Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider's stock valued at $4,233,000 after buying an additional 16,500 shares during the last quarter. Flax Pond Capital LLC purchased a new stake in Edap Tms in the fourth quarter valued at approximately $2,623,000. Finally, Financial Planning Navigators CORP purchased a new stake in Edap Tms in the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 62.74% of the company's stock.

Edap Tms News Summary

Here are the key news stories impacting Edap Tms this week:

• Positive Sentiment: HC Wainwright kept a "Buy" rating with a $10 price target and trimmed near‑term losses: they raised EPS forecasts for Q1–Q3 2026 (e.g., Q1 to ($0.18) from ($0.22); Q2 to ($0.16) from ($0.21); Q3 to ($0.22) from ($0.25)) and improved FY2026 to ($0.74) from ($0.84). The less‑negative near‑term outlook and a $10 target (well above current levels) support upside investor sentiment.
• Positive Sentiment: Major business press highlighted analyst bullishness on EDAP, reinforcing positive market perception and investor interest. Analysts Are Bullish on These Healthcare Stocks: EDAP TMS (EDAP), Ionis Pharmaceuticals (IONS)
• Neutral Sentiment: Coverage collecting broker projections for long‑range years (including an AmericanBankingNews piece summarizing FY2030 predictions). Long‑range forecasts can shape narrative but typically have limited immediate price impact versus near‑term earnings and clinical/news catalysts. Brokers Offer Predictions for Edap Tms FY2030 Earnings
• Negative Sentiment: HC Wainwright also cut FY2029 (from ($0.06) to ($0.10)) and some longer‑run estimates, and one headline framed the research as a "pessimistic forecast" — these items can temper investor enthusiasm because they highlight continued multi‑year losses. HC Wainwright Issues Pessimistic Forecast for Edap Tms NASDAQ: EDAP Stock Price

Edap Tms Company Profile

Edap Tms SA NASDAQ: EDAP is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.